# US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

> **NCT04594031** · PHASE1 · WITHDRAWN · sponsor: **ExCellThera inc.**

## Conditions studied

- Sickle Cell Disease
- Umbilical Cord Blood
- Hematopoietic Cell Proliferation

## Interventions

- **BIOLOGICAL:** ECT-001-CB (UM171-Expanded Cord Blood Transplant)

## Key facts

- **NCT ID:** NCT04594031
- **Lead sponsor:** ExCellThera inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07-13
- **Primary completion:** 2023-09-01
- **Final completion:** 2024-02-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Preference given to gene therapy approaches by the SCD research community and patients' associations
- **Last updated:** 2022-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04594031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04594031, "US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04594031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*